{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "", "close" : "", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
prnewswire

Abaxis, Inc. to Present at the UBS Global Life Sciences Conference

  • Press Release
  • Source: Abaxis, Inc.
  • On 11:53 am EDT, Wednesday September 16, 2009

UNION CITY, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX - News), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer, will present at the UBS Global Life Sciences Conference on Wednesday, September 23, 2009 at 12:00 p.m. ET. The conference will be held at the Grand Hyatt New York Hotel in New York City.

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

    Contact:  Clint Severson             Lytham Partners, LLC
              Chief Executive Officer    Joe Dorame, Joe Diaz & Robert Blum
              ABAXIS, Inc.               602-889-9700
              510-675-6500

Sponsored Links

Copyright © 2009 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.